Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment
Calidi Biotherapeutics (NYSE American: CLDI) is developing a precision genetic medicine platform for cancer treatment. The company's innovative approach focuses on using engineered viruses to deliver genetic medicines that can target both primary tumors and metastatic sites.
The development comes amid concerning cancer statistics, with 20 million annual cancer diagnoses globally and projections showing this number could reach 35 million by 2050. Currently, cancer claims nearly 10 million lives annually worldwide, highlighting the urgent need for more effective treatment options.
Calidi Biotherapeutics (NYSE American: CLDI) sta sviluppando una piattaforma di medicina genetica di precisione per il trattamento del cancro. L'approccio innovativo dell'azienda si basa sull'uso di virus ingegnerizzati per veicolare terapie genetiche in grado di colpire sia i tumori primari che le sedi metastatiche.
Questo sviluppo arriva in un contesto di dati preoccupanti sul cancro, con 20 milioni di diagnosi annuali a livello globale e proiezioni che indicano un aumento fino a 35 milioni entro il 2050. Attualmente, il cancro causa quasi 10 milioni di decessi ogni anno nel mondo, sottolineando l'urgenza di trovare opzioni terapeutiche pi霉 efficaci.
Calidi Biotherapeutics (NYSE American: CLDI) est谩 desarrollando una plataforma de medicina gen茅tica de precisi贸n para el tratamiento del c谩ncer. El enfoque innovador de la compa帽铆a se centra en utilizar virus dise帽ados para administrar medicamentos gen茅ticos que pueden atacar tanto tumores primarios como sitios metast谩sicos.
Este avance ocurre en medio de preocupantes estad铆sticas sobre el c谩ncer, con 20 millones de diagn贸sticos anuales a nivel mundial y proyecciones que indican que esta cifra podr铆a llegar a 35 millones para 2050. Actualmente, el c谩ncer causa casi 10 millones de muertes al a帽o en todo el mundo, lo que resalta la urgente necesidad de opciones de tratamiento m谩s efectivas.
Calidi Biotherapeutics (NYSE American: CLDI)電� 鞎� 旃橂毳� 鞙勴暅 鞝曤皜 鞙犾爠鞛� 鞚橅暀 頂岆灚韽检潉 臧滊皽頃橁碃 鞛堨姷雼堧嫟. 鞚� 須岇偓鞚� 順侅嫚鞝侅澑 鞝戧芳氩曥潃 鞙犾爠鞛� 鞚橃暯頀堨潉 鞝勲嫭頃橁赴 鞙勴暅 臁办瀾霅� 氚旍澊霟姢毳� 靷毄頃橃棳 鞗愲皽靹� 膦呾枒瓿� 鞝勳澊 攵�鞙� 氇憪毳� 響滌爜鞙茧 靷茧姅 雿� 欷戩爯鞚� 霊‰媹雼�.
鞚� 臧滊皽鞚� 鞝� 靹戈硠鞝侅溂搿� 鞐瓣皠 2,000毵� 瓯挫潣 鞎� 歆勲嫧鞚措澕電� 鞖半牑鞀る煬鞖� 韱店硠 靻嶌棎靹� 鞚措（鞏挫鞙茧┌, 2050雲勱箤歆� 鞚� 靾橁皜 3,500毵� 瓯挫棎 鞚措ゼ 瓴�鞙茧 鞓堨儊霅╇媹雼�. 順勳灛 鞎旍潃 鞝� 靹戈硠鞝侅溂搿� 毵る厔 瓯办潣 1,000毵� 氇呾潣 靸濍獏鞚� 鞎楈晞臧�瓿� 鞛堨柎 雿� 須臣鞝侅澑 旃橂氩曥潣 旮搓笁頃� 頃勳殧靹膘潉 氤挫棳欷嶋媹雼�.
Calidi Biotherapeutics (NYSE American: CLDI) d茅veloppe une plateforme de m茅decine g茅n茅tique de pr茅cision pour le traitement du cancer. L'approche innovante de l'entreprise se concentre sur l'utilisation de virus modifi茅s pour d茅livrer des m茅dicaments g茅n茅tiques capables de cibler 脿 la fois les tumeurs primaires et les sites m茅tastatiques.
Ce d茅veloppement intervient dans un contexte de statistiques pr茅occupantes sur le cancer, avec 20 millions de diagnostics annuels dans le monde et des projections indiquant que ce chiffre pourrait atteindre 35 millions d'ici 2050. Actuellement, le cancer cause pr猫s de 10 millions de d茅c猫s par an 脿 l'茅chelle mondiale, soulignant le besoin urgent de traitements plus efficaces.
Calidi Biotherapeutics (NYSE American: CLDI) entwickelt eine pr盲zise genetische Medizinplattform zur Krebsbehandlung. Der innovative Ansatz des Unternehmens konzentriert sich auf den Einsatz von konstruierten Viren zur Abgabe genetischer Medikamente, die sowohl prim盲re Tumore als auch metastatische Stellen gezielt angreifen k枚nnen.
Diese Entwicklung erfolgt vor dem Hintergrund besorgniserregender Krebsstatistiken mit 20 Millionen j盲hrlichen Krebsdiagnosen weltweit und Prognosen, die einen Anstieg auf 35 Millionen bis 2050 erwarten lassen. Derzeit fordert Krebs j盲hrlich fast 10 Millionen Todesf盲lle weltweit, was den dringenden Bedarf an wirksameren Behandlungsm枚glichkeiten unterstreicht.
- Developing innovative cancer treatment platform using engineered viruses
- Addressing a large and growing market with 20 million annual cancer diagnoses
- Platform targets both primary tumors and metastatic sites
- Early-stage development with no proven clinical results yet
- Faces significant competition in the cancer treatment market
NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- via 鈥� Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by ("NNW"), one of 70+ brands within聽the聽@听(), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
To view the full publication, 鈥淧recision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs,鈥� please visit:
An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide with these numbers expected to grow. The American Cancer Society projects that by 2050, 35 million people will be diagnosed with cancer every year. Despite significant progress made in treating the disease, there is still a desperate need 鈥� and an enormous market potential 鈥� for new and more effective cancer drugs.
Calidi Biotherapeutics Inc. is committed to developing a novel approach to treating cancer through the precise delivery of genetic medicines to both primary tumors and metastatic sites of disease. This cutting-edge platform, which harnesses engineered viruses that can target sites of cancer in the body and deliver potent genetic medicines to attack tumors, has the potential to revolutionize the way cancer is treated.
About Calidi Biotherapeutics Inc.
Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi鈥檚 novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi鈥檚 clinical-stage, off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi鈥檚 preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California.
For more information, visit the company鈥檚 website at聽.
NOTE TO INVESTORS:聽The latest news and updates relating to CLDI are available in the company鈥檚 newsroom at聽
About NetworkNewsWire
听(鈥淣NW鈥�) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within聽the聽听蔼听聽that delivers:听(1) access to a vast network of wire solutions via聽InvestorWire聽to efficiently and effectively reach a myriad of target markets, demographics and diverse industries;听(2) article and聽;听(3) 聽to ensure maximum impact;听(4)聽聽via IBN to millions of social media followers;聽and (5) a full array of tailored聽. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today鈥檚 market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
For more information, please visit聽
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished:
NetworkNewsWire
New York, NY
212.418.1217 Office
NetworkNewsWire is powered by聽
FAQ
What is Calidi Biotherapeutics (CLDI) developing for cancer treatment?
How large is the potential market for Calidi Biotherapeutics' (CLDI) cancer treatment?
What makes Calidi Biotherapeutics' (CLDI) cancer treatment approach unique?
How many cancer-related deaths occur annually worldwide according to CLDI's report?
What is the current development stage of Calidi Biotherapeutics' (CLDI) cancer treatment platform?
